AI Precision Biology Market
Every Market-Reports.com study delivers in-depth market sizing, growth forecasts, competitive intelligence, segmentation analysis, and regional insights — built from company filings, government statistics and trade data, and structured for confident strategic decision-making. Request a free report preview to see its scope, chapters and methodology before you buy.
Market Snapshot
2025 Market Size
US$ 956.0 million
Estimated Base Value
2035 Forecast
US$ 6.7 billion
Projected Market Value
CAGR 2026–2035
21.5%
Compound Annual Growth
Largest Segment
AI-driven Drug Discovery & Design Platforms
Fastest Growing Segment
Electric Commercial Vehicles
Leading Region
North America
Fastest Growing Region
Asia Pacific
Top Country
United States
By Market Share
Largest market
Key Players
Insitro
Emerging Players
Xaira Therapeutics, Genesis Therapeutics
AI Precision Biology Market Overview
The AI Precision Biology Market in Pharmaceuticals involves applying artificial intelligence and machine learning to biological data for drug discovery, development, and personalized medicine. This market provides solutions for advanced analytics of genomic, proteomic, clinical, and real-world data. Its primary users are pharmaceutical and biopharmaceutical companies, contract research organizations, and academic and research institutions seeking to enhance the precision, efficiency, and success rates of their research and development efforts. The aim is to deliver more effective and tailored therapeutic interventions and accelerate the introduction of new treatments.
The market is estimated at $956.0 Mn in 2025 and is forecast to reach $6.7 Bn in 2035, growing at a CAGR of 21.5% from 2025 to 2035. Demand is driven by the high costs associated with pharmaceutical R&D, the increasing complexity of biological data, and the need for faster drug development timelines. However, market expansion is constrained by limited access to diverse, high-quality biological data, challenges in navigating regulatory frameworks for AI-driven therapies, and a shortage of professionals skilled in both AI and precision biology.
The market is segmented by Type (AI-Driven Drug Discovery & Design Platforms, AI for Predictive & Prognostic Modeling), Technology (Machine Learning, Natural Language Processing), Application (Target Identification & Validation, Lead Optimization & De Novo Drug Design), End-User (Pharmaceutical & Biopharmaceutical Companies, Contract Research Organizations), Deployment (Cloud-Based, On-Premise), and Functionality (Predictive Modeling & Simulation, Omics Data Interpretation & Visualization). Geographically, it is served across North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Leading companies include Insitro, Recursion Pharmaceuticals, Exscientia, and BenevolentAI. The full report covers market trends, drivers, restraints, and opportunities.
Market Definition & Overview
The AI Precision Biology Market in Pharmaceuticals encompasses the application of artificial intelligence (AI) and machine learning (ML) technologies to biological data for drug discovery, development, and personalized medicine. This market leverages AI for advanced analytics of genomic, proteomic, clinical, and real-world data, facilitating target identification, lead optimization, biomarker discovery, and patient stratification. It aims to enhance the precision, efficiency, and success rates of pharmaceutical R&D, leading to more effective and tailored therapeutic interventions and accelerating the delivery of novel treatments to patients.
Scope
- Global market focus across all major regions
- Applications within the pharmaceutical and biotechnology industries
- Analysis of current market landscape and future trends
- Covers solutions for drug discovery and development phases
Inclusions
- AI platforms for novel drug target identification
- Machine learning tools for lead compound optimization
- AI-powered predictive analytics for clinical trial design
- Genomic and proteomic data analysis utilizing AI algorithms
- AI solutions for patient stratification in therapeutic areas
- Computational biology services integrating AI and ML
Exclusions
- General artificial intelligence software outside drug R&D
- AI applications in medical imaging diagnostics
- Traditional drug discovery services not incorporating AI
- AI solutions for pharmaceutical manufacturing processes
- AI applications solely focused on healthcare operations management
Market Size Forecast
Executive Summary
• The AI Precision Biology market is valued at $956.0 Mn in 2025 and is forecast to reach $6.7 Bn by 2035, reflecting a robust CAGR of 21.5% as demand accelerates across every major segment and region over the ten-year outlook.
• AI-driven Drug Discovery & Design Platforms leads the segment breakdown by current market share, underscoring where the bulk of near-term revenue and competitive activity within this market is concentrated today.
• North America commands the largest regional share at XX.X%, while Emerging Areas is expanding the fastest at a XX.X% CAGR, signalling where future growth is shifting.
• United States remains the single largest country-level market at XX.X% of global share, anchoring overall demand within its home region throughout the forecast period.
• Strategic alliances between technology giants and pharmaceutical incumbents are intensifying, creating a bifurcated market where specialized AI startups either partner or become acquisition targets for accelerated pipelines.
• Exponential growth in multi-omics data combined with advanced computational capabilities significantly catalyzes AI adoption, enabling unparalleled precision in target identification and patient stratification across therapeutic areas.
• Maturing machine learning models and evolving regulatory frameworks for AI-driven diagnostics are accelerating clinical translation, fostering investor confidence in novel precision biology applications globally.
• Oncology and rare diseases remain primary adoption drivers, yet neuroscience and immunology present significant emerging opportunities, with North America and Europe leading innovation in platform development.
• Substantial venture capital influx and strategic corporate investments are fueling innovative AI-first drug discovery platforms, driving intense competition and the emergence of specialized biotech ecosystems globally.
• The market is fundamentally shifting towards integrated AI platforms spanning discovery to development, promising to revolutionize R&D efficiency and significantly reduce time-to-market for novel, personalized therapies.
Key Market Takeaways
Critical findings and data points from this market research study.
Current Market Valuation
The AI Precision Biology Market held a valuation of $956.0 million in the base year, establishing a strong foundation for future growth within the pharmaceutical sector.
Robust Growth Projection
This market is set for significant expansion, exhibiting a Compound Annual Growth Rate (CAGR) of 21.5% throughout the forecast period.
Future Market Scale
By the forecast year, the AI Precision Biology Market is projected to reach an impressive $6.7 billion, underscoring its escalating importance and impact.
Drug Discovery Dominance
The drug discovery segment is anticipated to remain a dominant force, propelled by AI's capability to revolutionize target identification, lead optimization, and preclinical development.
North America Leadership
North America is expected to lead the market, driven by substantial R&D investments, advanced technological adoption, and a strong presence of pharmaceutical and biotech firms.
Personalized Medicine Trend
A notable trend driving market expansion is the accelerating adoption of AI for personalized medicine, enabling highly specific diagnostics and tailored therapeutic interventions.
Market Dynamics
Market Trends
- Generative AI adoption accelerates drug discovery pipelines.
- Multi-omics data integration is enhancing biological insights.
- Explainable AI (XAI) is becoming crucial for regulatory approval.
- Strategic partnerships between AI firms and pharma are increasing.
Growth Drivers
- High R&D costs push for more efficient AI-driven solutions.
- Complexity of biological data necessitates advanced AI analytics.
- Demand for accelerated drug development timelines is paramount.
- Advancements in AI algorithms are fueling market expansion.
Restraints
- Limited access to diverse, high-quality biological data hinders AI model training.
- Navigating complex regulatory frameworks for AI-driven therapies poses significant hurdles.
- High initial investment costs and infrastructure demands can impede adoption.
- A notable shortage of professionals skilled in both AI and precision biology limits growth.
Opportunities
- AI platforms can revolutionize personalized medicine approaches.
- AI offers significant potential in identifying new drug targets.
- Optimizing clinical trials with AI promises faster drug approvals.
- Expanding AI applications into novel biotherapeutics presents growth.
Market Dynamics Framework · 2026–2035
Need Custom Data for This Market?
Get tailored segmentation, deeper competitive intelligence, or region-specific deep dives from our analyst team.
Market Segmentation
| Segment | Sub-segments |
|---|---|
| By Type | AI-Driven Drug Discovery & Design PlatformsAI for Predictive & Prognostic ModelingAI-Powered Omics Data Analysis SolutionsAI-Enabled Clinical Trial Optimization SystemsAI for Personalized Medicine Decision SupportAI-Driven Biomarker Discovery & DiagnosticsAI Research & Development Services |
| By Technology | Machine LearningNatural Language ProcessingComputer VisionPredictive AnalyticsKnowledge Graph & ReasoningRobotics & Intelligent Automation |
| By Application | Target Identification & ValidationLead Optimization & De Novo Drug DesignClinical Trial OptimizationPatient Stratification & Personalized TreatmentBiomarker DiscoveryDisease Diagnostics & MonitoringDrug RepurposingPharmacovigilance & Drug Safety |
| By End-User | Pharmaceutical & Biopharmaceutical CompaniesContract Research OrganizationsAcademic & Research InstitutionsHospitals & ClinicsDiagnostic CentersBioinformatics & Computational Biology Service Providers |
| By Deployment | Cloud-BasedOn-PremiseHybrid DeploymentManaged Services |
| By Functionality | Predictive Modeling & SimulationOmics Data Interpretation & VisualizationPersonalized Treatment Recommendation & DosingDrug Candidate PrioritizationReal-World Evidence GenerationClinical Decision SupportAutomated Workflow & Process Optimization |
Regional Analysis
- North America leads the AI Precision Biology market due to its robust R&D ecosystem, substantial venture capital investments, and the presence of numerous biotech and pharmaceutical giants. Early adoption of AI in drug discovery and personalized medicine further solidifies its dominant position.
- Asia-Pacific is projected to be the fastest-growing region, driven by escalating healthcare expenditures, vast patient populations, and proactive government support for AI and biotechnology. Countries like China and India are rapidly integrating AI into drug development processes.
- Europe shows a noteworthy trend towards integrating strict ethical AI frameworks and data privacy regulations like GDPR into precision biology. This fosters trust and secure data sharing, alongside increasing cross-border collaborations and specialized national initiatives for AI in healthcare.
| North AmericaXX.X% | EuropeXX.X% | Asia PacificXX.X% | Latin AmericaXX.X% | Middle East & AfricaXX.X% |
North America
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Leading the market with significant R&D investment, presence of major pharmaceutical companies, and strong venture capital funding for AI in biotech.
- Benefits from advanced technological infrastructure and a highly skilled workforce.
Latin America
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- A developing market with increasing healthcare demands and growing interest in leveraging AI for drug discovery and personalized medicine.
- Regulatory challenges and infrastructure limitations present hurdles but also opportunities for focused growth.
Europe
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- A mature pharmaceutical market with robust academic research and growing government support for AI integration in healthcare.
- Faces fragmentation across countries but boasts strong foundational science and innovation hubs.
Asia Pacific
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Experiencing rapid expansion driven by massive investments in R&D, a burgeoning patient population, and government initiatives promoting AI and biotech.
- Key players include China, Japan, and India, fostering innovation and adoption.
Middle East & Africa
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Emerging as a strategic hub with significant government initiatives to diversify economies through technology and healthcare investments, particularly in the UAE and Saudi Arabia.
- Adoption of AI in precision biology is nascent but rapidly accelerating.
Country Analysis
United States and Brazil represent the largest country-level markets, with growth across the remaining countries shaped by local regulatory, infrastructure, and demand-side factors specific to each geography.
| # | Country | Market Size | CAGR | Key Driver |
|---|---|---|---|---|
| 1 | United States | US$ XX.X Mn | XX.X% | The U.S. leads in AI precision biology due to extensive pharmaceutical R&D, a robust biotech startup ecosystem, and significant venture capital investment in drug discovery platforms. It benefits from top-tier academic research institutions and a supportive regulatory environment for innovative therapies. |
| 2 | Brazil | US$ XX.X Mn | XX.X% | As the largest economy in Latin America, Brazil has a significant healthcare market and increasing investment in R&D, including genomics and digital health. Its large population provides a rich dataset for AI-driven precision medicine applications. |
| 3 | Germany | US$ XX.X Mn | XX.X% | Germany's strong pharmaceutical industry, advanced engineering capabilities, and significant investment in health tech drive its precision biology market. A focus on personalized medicine and robust research infrastructure makes it a key player. |
| 4 | China | US$ XX.X Mn | XX.X% | China is making massive investments in AI and biotech, supported by a huge patient population and a rapidly expanding R&D landscape. Government backing and a focus on becoming a leader in health innovation are fueling its rapid growth in precision biology. |
| 5 | Israel | US$ XX.X Mn | XX.X% | Israel is a global leader in digital health and AI innovation, boasting a thriving startup ecosystem and significant R&D in biotech and pharma. Its strong academic-industry collaboration drives advancements in AI-powered drug discovery and diagnostics. |
Countries Covered (29)
United States, Canada, Mexico, Brazil, Argentina, Rest of Latin America, Germany, United Kingdom, France, Switzerland, Netherlands, Italy, Spain, Russia, Rest of Europe, China, Japan, South Korea, India, Taiwan, Singapore, Australia, Malaysia, Rest of Asia Pacific, Israel, Saudi Arabia, United Arab Emirates, South Africa, Rest of Middle East & Africa
Competitive Landscape
| # | Company | Share | Key Strategy | Key Note | Key Developments | Key Products |
|---|---|---|---|---|---|---|
| 1 | Insitro | XX.X% | Leverage human genetics, functional genomics, and machine learning to build predictive disease models and discover novel drug targets. | — | — | Target Discovery PlatformDrug Discovery PartnershipsiPSC-based disease models |
| 2 | Recursion Pharmaceuticals | XX.X% | Systematically map human biology through its automated wet-lab and AI-driven platform to accelerate drug discovery. | — | — | Recursion OSPhenomapsTarget-agnostic drug discovery+1 |
| 3 | Exscientia | XX.X% | Design novel small molecule candidates faster and more efficiently using AI, moving from target to clinic. | — | — | AI-driven drug discovery platformPersonalized MedicineEXSCALATE platform |
| 4 | BenevolentAI | XX.X% | Combine AI and machine learning with biomedical science to discover new drug targets and develop novel treatments. | — | — | Benevolent PlatformBenevolentAI knowledge graphDrug Discovery Partnerships |
| 5 | Schrödinger | XX.X% | Provide a leading physics-based computational platform for drug discovery and materials science. | — | — | MaestroLiveDesignFEP++1 |
Market Positioning Map
Market share vs. growth outlook — bubble size is market share, bubble color is relative profitability
Companies Profiled (20)
Insitro, Recursion Pharmaceuticals, Exscientia, BenevolentAI, Schrödinger, Valo Health, Generate Biomedicines, Insilico Medicine, Relay Therapeutics, AbCellera, Tempus, Owkin, Deep Genomics, PathAI, ConcertAI, Atomwise, Immunai, Terray Therapeutics, Cyclica, Healx
The global AI Precision Biology market features a competitive landscape led by Insitro, Recursion Pharmaceuticals, Exscientia, BenevolentAI, Schrödinger, and Valo Health, among other established and emerging players. Market participants continue to compete on product innovation, pricing strategy, geographic expansion, and strategic partnerships to strengthen their position in this evolving market.
* Market share estimates based on company revenue disclosures and public sources; undisclosed figures are marked.
Company Profiles
Insitro
Recursion Pharmaceuticals
Exscientia
BenevolentAI
Schrödinger
Valo Health
Generate Biomedicines
Insilico Medicine
Relay Therapeutics
AbCellera
Tempus
Owkin
Deep Genomics
PathAI
ConcertAI
Atomwise
Immunai
Terray Therapeutics
Cyclica
Healx
* Classification reflects relative market share and maturity, derived from revenue analysis and public disclosures.
Ready to Make Data-Driven Decisions?
Purchase the full report or request a custom engagement. Get analyst support, scenario modelling, and real-time dashboard access.
Recent Market Developments
AI Drug Discovery Pioneer Secures US$ XX.X in Series C Funding
Insilico Medicine, a leader in AI-driven drug discovery, closed a US$ XX.X Series C funding round to accelerate its pipeline of AI-discovered and AI-designed drug candidates into clinical trials across multiple therapeutic areas.
Pfizer Enters Multi-Year AI Partnership with BenevolentAI for Precision Oncology
Pfizer announced a strategic collaboration with BenevolentAI to leverage its AI platform for novel target identification and drug candidate optimization in precision oncology, aiming to develop more targeted therapies with improved patient outcomes.
Exscientia Unveils AI-Powered 'Digital Patient Twin' Platform for Preclinical Trials
Exscientia launched its innovative 'Digital Patient Twin' platform, which uses AI to create virtual patient models for simulating drug responses, drastically reducing the time and cost associated with early-stage drug development and toxicity screening.
Novartis Acquires AI Biotech 'RepurposeRx' to Bolster Rare Disease Pipeline
Novartis announced the acquisition of RepurposeRx, an AI-driven biotech specializing in drug repurposing for rare and neglected diseases. This move aims to integrate cutting-edge AI capabilities to accelerate the identification of existing drugs for new therapeutic indications.
Report Data Parameters
| Parameter | Value |
|---|---|
| Base Year | 2025 |
| Forecast Year | 2035 |
| Historical Period | 2019–2025 |
| Market Size (Base Year) | $956.0 Mn |
| Market Size (Forecast) | $6.7 Bn |
| CAGR | 21.5% |
| Forecast Period | 2026–2035 |
| Geography | Global |
| Countries Covered | 29 Countries |
| Segments Covered | 6 Segments, 38 Sub-segments |
| Companies Profiled | 31 Companies |
Report Value
Why Choose This Report
Complete Market Size
Market sizing for the base year and a 10-year forecast across three scenarios.
Segment Analysis
Deep-dive segmentation by product, application, end-user, and technology verticals.
Country Analysis
Country-level market data for every country in the report scope, across all major regions.
Company Profiles
Profiles of the leading companies, with disclosed financials, strategy and market share.
Market Share
Detailed competitive market share analysis with trend mapping and benchmarking.
Competitive Intelligence
SWOT, Porter's Five Forces, and competitive positioning across market leaders.
Scenario Analysis
Three-scenario modelling (Base / Optimistic / Conservative) with CAGR decomposition.
Regulatory Review
Regulatory landscape, compliance requirements, and policy impact analysis by region.
Strategic Analysis · Management Insights · CXO Insights
Executive Strategic & Intelligence Report
A board-ready strategic deck built on the AI Precision Biology Market report: eleven chapters and an appendix, from market sizing to the board decisions, delivered as a PDF with an Excel datapack. US$3,000 per market, prepared after your order.
What to expect in the Executive Report for this market
- About 400 slides, 11 chapters and an appendix. Built on this report's own numbers, so every figure matches the report and the Excel.
- Market size and forecast to 2035. By segment, sub-segment, region and country, with conservative, base and optimistic cases.
- An analysis page after every exhibit. The key insight, ten specific points and the decision it implies for leaders, challengers, entrants and investors.
- Competitive intelligence. Shares and positioning, capability benchmark, strategies, recent moves and acquisition screening.
- Customers, technology and business models. Who buys and why, AI and technology impact, pricing, channels and go-to-market by segment.
- Risks and scenarios. Risk register, four future scenarios with signposts, and early-warning indicators with thresholds.
- Opportunities and the board decisions. Opportunity scoring, strategic options, roadmap, capability gaps, decision matrix and a 90-day plan.
- PDF, Excel datapack and PowerPoint. A bookmarked PDF, the full Excel datapack and editable infographic slides for your own decks.
US$3,000 per market · bought online, prepared after your order and emailed to you
See a full example report →Only need the headline view? Market Snapshot (PDF) + Excel Datasheet · 10–20 slide PDF + Excel
A CEO-level executive summary of the market in 10–20 slides - size and forecast, growth by segment and region, the leading countries and companies, key trends and the outlook - plus the Excel datasheet. A short executive view of this market, not the full analysis - PDF and Excel, prepared and emailed to you after your order.
Trusted by strategy teams, investors & global enterprises
What Our Clients Say
Verified reviews from enterprise clients
“The depth of analysis and quality of data is unparalleled. This report directly informed our $50M market expansion strategy and helped us prioritise the right geographies.”
VP, Corporate Strategy
Industrial manufacturing company
“Exceptional research quality. The competitive landscape section alone saved our team months of primary research effort and gave us a clear view of the opportunity.”
Director, Investment Research
Private equity firm
“We now use these reports in every planning cycle. The regional granularity, and the same numbers across the report, the dashboard and the Excel, save our team real time.”
Head of Market Intelligence
Specialty chemicals company
Frequently Asked Questions
Common questions about this report and our research
The AI Precision Biology market is estimated at $956.0 Mn in 2025. It is forecast to reach $6.7 Bn by 2035, reflecting significant expansion in the application of AI within pharmaceutical R&D.
The AI Precision Biology market is forecast to grow at a Compound Annual Growth Rate (CAGR) of 21.5% from 2025 to 2035. This growth is driven by the increasing demand for efficient drug discovery and personalized medicine solutions.
The main segments include AI-Driven Drug Discovery & Design Platforms, Machine Learning technologies, Target Identification & Validation applications, Pharmaceutical & Biopharmaceutical Companies as end-users, Cloud-Based deployment, and Predictive Modeling & Simulation functionality. The market is also segmented by region.
Leading companies in this market include Insitro, Recursion Pharmaceuticals, Exscientia, BenevolentAI, Schrödinger, Valo Health, Generate Biomedicines, Insilico Medicine, Relay Therapeutics, AbCellera, Tempus, and Owkin. These companies are developing and deploying AI solutions for pharmaceutical applications.
The AI Precision Biology market report covers the market definition, scope, and detailed segmentation by Type, Technology, Application, End-User, Deployment, and Functionality. It also analyzes market trends, growth drivers, restraints, opportunities, and the competitive landscape with profiles of leading companies.
The Single User and Enterprise licences include the full PDF report, the PowerPoint (PPT), the Excel data workbook and the interactive Online Dashboard. The Online Dashboard gives online access to the snapshot and datasheet with export features, and the Market Snapshot is an executive summary in PDF with the Excel data sheet.
Yes. Request a free report preview: its scope, every chapter and what it contains, the methodology and the headline figures. The full report is a paid product.
We accept credit/debit cards (Visa, Mastercard, Amex), bank wire transfer, and purchase orders for enterprise clients. All transactions are secured with 256-bit SSL encryption.
Buy This Report
Choose the format that fits your budget
Digital delivery — all sales are final. See our Refund Policy and Terms & Conditions.
Strategic deck for this market
Executive Strategic & Intelligence Report
About 400 board-ready slides: every exhibit with its analysis and the decision it implies. Prepared for this market after your order and emailed to you.
Need to go deeper?
Intelligence services for this market
- Competitor benchmarking →
- Market entry & expansion →
- Product & growth opportunities →
- Investment & acquisition due diligence →
What's Included
Similar Reports
Precision Biology Platform Market
$7.0 Bn in 2025 · 6.0% CAGR
AI Synthetic Biology Platform Market
$2.7 Bn in 2025 · 18.0% CAGR
Digital Biology Market
$4.3 Bn in 2025 · 21.6% CAGR
Precision Biomanufacturing Market
$2.8 Bn in 2025 · 18.2% CAGR
Precision Cell Engineering Market
$1.1 Bn in 2025 · 26.8% CAGR
Precision Cell Manufacturing Market
$846.0 Mn in 2025 · 24.2% CAGR
Precision Immunology Market
$4.7 Bn in 2025 · 16.3% CAGR
Precision Medicine Market
$60.0 Bn in 2025 · 10.0% CAGR